Respiratory Disease Panel
PCL’s Respiratory Disease Panel is focused on serving:
- Skilled Nursing Facilities
- ENT Physicians
- Geriatric, Primary Care & Family Physicians
- Pediaticians
Respiratory Disease Panel Benefits
- Testing for both infections and viruses has a large impact of the types of treatments that will be effective.
- Quickly identifies all organisms and pathogens in the respiratory tract and potential bacterial antibiotic resistance allowing providers to offer more effective, supportive care.
Respiratory Disease Statistics
- Every year, influenza leads to respiratory tract infections in 5-15% of the population and severe illness in 3-5 million people.
- As of June 2021, the United States has seen over 33 million COVID-19 cases and nearly 600 thousand associated deaths.
The Respiratory Panel detects the following:
- BACTERIAL
- Bordetella (Pan)
- Bordetella pertusus
- Chlamydophila pneumoniae
- Haemophiilus influenzae
- Klebsiella pneumoniae complex
- Legionella pneumophila
- Mycoplasma pneumoniae
- Staphylococcus aureus
- Streptocccus pneumoniae
- VIRAL
- Adenovirus
- Coronavirus 229E
- Coronavirus HKU1
- CoronavirusNL63
- Coronavirus OC43
- Enterovirus (pan assay)
- Enterovirus D68
- Herpevirus (HHV6)
- HHV4 (Epstein-Barr virus)
- HHV5 (cytomegalovirus)
- Metapneumovirus (hMPV)
- Influenza A (pan)
- Influenza A/H1-2009
- Influenza A/H3
- Influenza B
- Parainfluenza virus 1
- Parainfluenza virus 2
- Parainfluenza virus 3
- Parainfluenza virus 4
- Respiratory Syncytial Virus (RSV A)
- Respiratory Syncytial Virus (RSV B)
- Rhinovirus
- SARS-CoV-2
Results will become available online within 24 to 48 hours of specimen receipt followed by hard copy in the mail and fax if requested.